/PRNewswire/ AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment.
AffyImmune Therapeutics Announces Addition of Dr Jim Mulé to its Scientific Advisory Board prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NATICK, Mass., May 25, 2021 /PRNewswire/ AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that co-founder and CEO Dr. Moonsoo Jin was awarded a Research Project Grant (R01). The grant,
CAR T Cells for Advanced Thyroid Cancer, will contribute to supportive studies related to AffyImmune s Phase 1 clinical trial,
Study of AIC100 in Relapsed/Refractory Thyroid Cancer at Weill Cornell Medical College in New York, New York.
Dr. Jin commented, The primary challenge in the CAR T field is balancing efficacy and toxicity. This grant allows us to continue our work in striking that balance to treat solid tumors by iterating from bench to bedside. In doing so, we can potentially develop the most effective CAR T therapies for solid tumors.
AffyImmune Co-founder Dr Moonsoo Jin Receives Highly Selective R01 Grant from NCI prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers,.